share_log

Needham Downgrades Cogent Biosciences to Hold, Maintains Price Target to $15

Benzinga ·  Dec 11 07:18  · Ratings

Needham analyst Ami Fadia downgrades Cogent Biosciences (NASDAQ:COGT) from Buy to Hold and maintains the price target from $15 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment